---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005356"
form_type: "8-K"
ticker: null
cik: "0001310527"
company_name: "QSAM Biosciences, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:26:19.748639+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# QSAM Biosciences to be acquired by Telix for ~$33.1M shares plus up to $90M CVRs

## Summary
- Telix will acquire QSAM via two-step merger; total base consideration ~$33.1M in Telix shares (at $7.5745/share).
- QSAM stockholders receive 0.876 Telix shares per pre-reverse-split share (est. $6.63/share value).
- Up to $90M in contingent value rights (CVRs) on regulatory/commercial milestones over 10 years.
- Reverse stock split (1:1000 to 1:2000) to be effected before close; all preferred converted.
- Lock-up agreements for officers/directors on Telix shares received for 12 months post-close.

## SEC filing metadata
- accession: 0001493152-24-005356
- form_type: 8-K
- cik: 0001310527
- company_name: QSAM Biosciences, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005356
- JSON: https://secwatch.observer/filing/0001493152-24-005356.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005356.txt

## Key facts
- Governance Changes
  QSAM Biosciences, Inc.: Proposed reverse stock split requiring amendment to Amended and Restated Certificate of Incorporation.
  - Change: charter amendment
  source text: Upon the QSAM Board’s approval of the Reverse Split ratio, QSAM shall file an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm
- Material Agreements
  QSAM Biosciences, Inc. entered into Agreement and Plan of Merger with Telix Pharmaceuticals Limited, Cyclone Merger Sub I, Inc., Cyclone Merger Sub II, Inc., and David H. Clarke (effective 2024-02-07).
  - Action: entry
  - Agreement: merger
  - Counterparty: Telix Pharmaceuticals Limited, Cyclone Merger Sub I, Inc., Cyclone Merger Sub II, Inc., and David H. Clarke
  - Effective: 2024-02-07
  source text: On February 7, 2024, QSAM Biosciences, Inc. (“QSAM”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Telix Pharmaceuticals Limited
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.